After over half a decade leading OXcan, Peter has made significant contributions to establishing OXcan at the forefront of liquid biopsy/AI-based early cancer detection. Peter has built invaluable connections with leading cancer treatment centres, commercial partners, and industry collaborators, and established a network of thought leaders in the lung cancer space.
Additionally, Peter has led OXcan through several fund-raising rounds, including the closing of the recent Series A Round and built credible connections with several top tier investors.
Peter leaves OXcan well positioned in a growing market and having the financial strength to deliver its business plan.
We would like to thank Peter for the indispensable and significant role he has played in building OXcan’s business to date.